HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIOLASE inks deal with P&G

This article was originally published in The Rose Sheet

Executive Summary

Dental laser company BIOLASE announces Jan. 25 it has signed a definitive licensing agreement with Procter & Gamble to provide intellectual property for the development of consumer products. P&G paid the Irvine, Calif. firm an upfront fee of $3 mil. and will pay BIOLASE royalties based on product sales, milestone payments and quarterly payments of $250,000 until the first product is launched. "This agreement with P&G opens the door for BIOLASE to participate in the consumer market alongside a proven leader in consumer products. We look forward to P&G bringing to the market new consumer products through this relationship," BIOLASE President and CEO Jeffrey W. Jones says. BIOLASE's LaserSmile system uses a laser to perform soft tissue and cosmetic procedures, including teeth whitening...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014504

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel